European Heart Journal Advance Access originally published online on July 17, 2006
European Heart Journal 2006 27(16):1954-1964; doi:10.1093/eurheartj/ehl146
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stroke prophylaxis in atrial fibrillation: who gets it and who does not?
Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study)
1 Karolinska Institute at South Hospital, Stockholm, Sweden
2 Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
3 AstraZeneca, Mölndal, Sweden
4 Department of Biostatistics, South Hospital, Karolinska Institute, Stockholm, Sweden
5 Department of Cardiology, South Hospital, Karolinska Institute, Stockholm, Sweden
Received 18 January 2006; revised 10 May 2006; accepted 23 June 2006; online publish-ahead-of-print 17 July 2006.
* Corresponding author: Cardiology Clinic, Nacka Hospital Lasarettsvägen 4, S-13183 Nacka, Sweden. Tel: +46 8 601 53 10; fax: +46 8 601 53 16. E-mail address: leif.friberg{at}stockholm.bonet.se
Aims Underuse of warfarin for stroke prophylaxis in atrial fibrillation (AF) is extensive and represents a major problem in clinical practice. To identify factors associated with warfarin treatment in eligible AF patients.
Methods and results The study population consisted of all Swedish resident AF patients at the Stockholm South General Hospital during 2002 (n=2796). Medical records were examined and complemented by data from the Swedish National Hospital Discharge Register. Sixty-eight percent of the patients (1898/2796) had indications, and no apparent contraindications for warfarin treatment. Of these 54% (1029/1898) got warfarin. Factors favouring warfarin treatment after adjustment for other factors were history of ischaemic stroke, an implanted pacemaker, treatment in a cardiology rather than internal medicine ward and valvular defect. Factors associated with a reduced likelihood of warfarin treatment were paroxysmal type of AF and age >80 years. Important risk factors for stroke in AF like heart failure, hypertension, and diabetes did not increase the chances of warfarin treatment.
Conclusion Risk stratification using known risk factors of stroke seems to affect warfarin treatment only to a minor degree in clinical practice. Undertreatment was particularly common in patients with paroxysmal AF and in patients aged >80 years and calls for improved clinical routines in accordance with international guidelines.
Key Words: Atrial fibrillation Thromboembolism Anticoagulation Warfarin Aspirin Guidelines Adherence
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Meiltz, M. Zimmermann, P. Urban, A. Bloch, and on behalf of the Association of Cardiologists of t Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world Europace, June 1, 2008; 10(6): 674 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L Garwood and T. L Corbett Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls Ann. Pharmacother., April 1, 2008; 42(4): 523 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Friberg, N. Hammar, H. Pettersson, and M. Rosenqvist Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF) Eur. Heart J., October 1, 2007; 28(19): 2346 - 2353. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Friberg and on behalf of the SCAF study group Stroke prophylaxis in patients with atrial fibrillation: what can we do about it?: reply Eur. Heart J., May 1, 2007; 28(9): 1173 - 1173. [Full Text] [PDF] |
||||
![]() |
M. Naunton Stroke prophylaxis in patients with atrial fibrillation: what can we do about it? Eur. Heart J., May 1, 2007; 28(9): 1172 - 1173. [Full Text] [PDF] |
||||
![]() |
O. M. Jolobe Stroke prophylaxis in atrial fibrillation Eur. Heart J., October 1, 2006; 27(19): 2370 - 2370. [Full Text] [PDF] |
||||



